---
title: "UBS' Investment Ratings and TPs on CRO Stocks (Table)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292579364.md"
description: "UBS published a research report providing investment ratings and target prices for several CRO stocks. The report lists 'Buy' ratings with specific target price adjustments for Wuxi AppTec, Wuxi Bio, Wuxi XDC, Pharmaron, and Tigermed, alongside current short selling data as of July 14, 2026."
datetime: "2026-07-14T07:00:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292579364.md)
  - [en](https://longbridge.com/en/news/292579364.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292579364.md)
generator: "portal-rs"
---

# UBS' Investment Ratings and TPs on CRO Stocks (Table)

UBS published a research report listing the investment ratings and target prices for CRO stocks as follows:

Stock | Investment Rating | TP (HKD)

WUXI APPTEC (02359.HK) +8.000 (+5.277%) Short selling $166.59M; Ratio 32.332% | Buy | HKD171.2 -> HKD176.5

WUXI BIO (02269.HK) +1.140 (+3.055%) Short selling $94.37M; Ratio 16.551% | Buy | HKD51.1

WUXI XDC (02268.HK) +1.250 (+2.176%) Short selling $30.47M; Ratio 18.993% | Buy | HKD89.4 -> HKD87.4

PHARMARON (03759.HK) +1.400 (+6.306%) Short selling $24.28M; Ratio 7.613% | Buy | HKD30 -> HKD31.8

TIGERMED (03347.HK) +1.300 (+3.583%) Short selling $10.61M; Ratio 31.294% | Buy | HKD52 -> HKD51.3

(gc/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-14 12:25.)

### Related Stocks

- [300759.CN](https://longbridge.com/en/quote/300759.CN.md)
- [02268.HK](https://longbridge.com/en/quote/02268.HK.md)
- [03759.HK](https://longbridge.com/en/quote/03759.HK.md)
- [03347.HK](https://longbridge.com/en/quote/03347.HK.md)
- [300347.CN](https://longbridge.com/en/quote/300347.CN.md)
- [02359.HK](https://longbridge.com/en/quote/02359.HK.md)
- [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md)
- [603259.CN](https://longbridge.com/en/quote/603259.CN.md)
- [02269.HK](https://longbridge.com/en/quote/02269.HK.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)

## Related News & Research

- [WuXi Biologics wins BioPharma APAC spot on 2026 sustainable biopharma list](https://longbridge.com/en/news/296188176.md)
- [WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO](https://longbridge.com/en/news/296188677.md)
- [WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence](https://longbridge.com/en/news/296174802.md)
- [GUBRA: Biotech revenue normalized post-AbbVie deal; CRO rebounded with 11% growth and profitability](https://longbridge.com/en/news/296439475.md)
- [GUBRA: Revenue fell sharply after last year's AbbVie deal, but pipeline and CRO growth continued](https://longbridge.com/en/news/296439393.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**